to investigate whether targeting p75NTR is a potential therapeutic strategy for treating peripheral demyelinating diseases, we sought to first determine the level of p75NTR expression in injured peripheral nerves of rats subjected to EAN at disease peak (day 17) and age-matched health control (non EAN) rats (Fig. 1). This evidence concerns the gene NGFR and demyelinating disease.